EllenKellyRitchieMD

Hematologic Oncology

Associate Clinical Professor of Medicine, Weill Cornell Medical College

Overview of Dr. Ritchie

Dr. Ellen Ritchie is a malignant hematologist in New York, NY and is affiliated with Weill Cornell Medicine-New York Presbyterian Hospital in NYC. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 20 years. She specializes in hematologic oncology and is experienced in leukemia, MDS, MPNs. She has more than 100 publications and over 500 citings.

Office
520 E 70th St
New York, NY 10021
Book by Phone+1(256) 369-0151

Fax+1 646-962-1605

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2000 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997

Certifications & Licensure

NY State Medical License 1999 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Start of enrollment: 2013 Jan 01
Terminated
Phase 2
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia Start of enrollment: 2013 Aug 01
Active, not recruiting
Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 2
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) Start of enrollment: 2017 Apr 25
Active, not recruiting
Phase 2
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia Start of enrollment: 2017 Oct 19
Completed
Phase 2
CPX-351+GO in Subjects 55 Years Old, or Older, With AML Start of enrollment: 2019 Aug 23
Terminated
Phase 1
Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

36 citations
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
Srdan Verstovsek, Moshe Talpaz, Ellen K. Ritchie, Martha Wadleigh, Olatoyosi Odenike
Leukemia. 2017-02-01
19 citations
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
Gail J. Roboz, Pinkal Desai, Sangmin Lee, Ellen K. Ritchie, Eric S. Winer
Leukemia & Lymphoma. 2021-02-13
12 citations
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.
Jiwon Kim, Spencer Krichevsky, Lola Xie, Maria Chiara Palumbo, Sara Rodriguez-Diego
Journal of the American Society of Echocardiography. 2019-10-03

Journal Articles

Somatic Mutations Precede Acute Myeloid Leukemia Years Before Diagnosis
Sangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature

Abstracts/Posters

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results ...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Recombinant Interferon-_ Reduces Thrombotic Events in Patients with Polycythemia Vera
Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Trial Patient Shortage Will Hinder the Progress of AML Drug Development
Ellen Ritchie, MD, Op-Med, Orlando, FL, 12/7/2019
Join now to see all

Lectures

CPX-351 As First Intensive Therapy for Elderly Patients with AML
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensiv...
2019 ASCO Annual Meeting - 6/1/2019
Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).
2019 ASCO Annual Meeting - 6/1/2019
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Clinical Trial Patient Shortage Will Hinder the Progress of AML Drug DevelopmentDecember 2018

Press Mentions

Nobody Wants Cancer. But a ‘Big C’ Label Has Surprising UpsidesMarch 11th, 2021
$Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting$
Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 2nd, 2019
Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness MonthSeptember 1st, 2017
Join now to see all

Professional Memberships

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Missouri - HMO/POS
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment